Prudent Scots pay for Lilly's Byetta, GSK's Votrient and Pfizer's Fragmin
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology agency, gave somewhat restricted reimbursement approval to a number of drugs including Lilly's Byetta (exenatide) in diabetes, a restricted approval for GSK's Votrient (pazopanib) in advanced renal cell carcinoma, and Pfizer's low molecular weight heparin, Fragmin, in symptomatic venous thromboembolism.